Monthly Archives: June 2022

Efficient terminal erythroid differentiation requires the APC/C cofactor Cdh1 to limit replicative stress in erythroblasts | Scientific Reports -…

Posted: June 22, 2022 at 2:18 am

Dzierzak, E. & Philipsen, S. Erythropoiesis: Development and differentiation. Cold Spring Harb. Perspect. Med. 3, a011601a011601 (2013).

PubMed PubMed Central Article CAS Google Scholar

Hattangadi, S. M., Wong, P., Zhang, L., Flygare, J. & Lodish, H. F. From stem cell to red cell: Regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. Blood 118, 62586268 (2011).

CAS PubMed PubMed Central Article Google Scholar

Mei, Y., Liu, Y. & Ji, P. Understanding terminal erythropoiesis: An update on chromatin condensation, enucleation, and reticulocyte maturation. Blood Rev. 46, 100740 (2021).

CAS PubMed Article Google Scholar

Steinman, R. A. Cell cycle regulators and hematopoiesis. Oncogene 21, 34033413 (2002).

CAS PubMed Article Google Scholar

Walkley, C. R., Sankaran, V. G. & Orkin, S. H. Rb and hematopoiesis: Stem cells to anemia. Cell Div. 3, 13 (2008).

PubMed PubMed Central Article CAS Google Scholar

Teixeira, L. K. & Reed, S. I. Ubiquitin ligases and cell cycle control. Annu. Rev. Biochem. 82, 387414 (2013).

CAS PubMed Article Google Scholar

Zhou, Z., He, M., Shah, A. A. & Wan, Y. Insights into APC/C: From cellular function to diseases and therapeutics. Cell Div. 11, 118 (2016).

Article CAS Google Scholar

Chang, L. & Barford, D. Insights into the anaphase-promoting complex: A molecular machine that regulates mitosis. Curr. Opin. Struct. Biol. 29, 19 (2014).

CAS PubMed Article Google Scholar

Eguren, M., Manchado, E. & Malumbres, M. Non-mitotic functions of the anaphase-promoting complex. Semin. Cell Dev. Biol. 22, 572578 (2011).

CAS PubMed Article Google Scholar

Qiao, X., Zhang, L., Gamper, A. M., Fujita, T. & Wan, Y. APC/C-Cdh1: From cell cycle to cellular differentiation and genomic integrity. Cell Cycle 9, 39043912 (2010).

CAS PubMed PubMed Central Article Google Scholar

Wsch, R., Robbins, J. A. & Cross, F. R. The emerging role of APC/CCdh1 in controlling differentiation, genomic stability and tumor suppression. Oncogene 29, 110 (2010).

PubMed Article CAS Google Scholar

Engelbert, D., Schnerch, D., Baumgarten, A. & Wsch, R. The ubiquitin ligase APCCdh1 is required to maintain genome integrity in primary human cells. Oncogene 27, 907917 (2008).

CAS PubMed Article Google Scholar

Garca-Higuera, I. et al. Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat. Cell Biol. 10, 802811 (2008).

PubMed Article CAS Google Scholar

Sigl, R. et al. Loss of the mammalian APC/C activator FZR1 shortens G1 and lengthens S phase but has little effect on exit from mitosis. J. Cell Sci. 122, 42084217 (2009).

CAS PubMed Article Google Scholar

Yuan, X., Srividhya, J., De Luca, T., Lee, J.-H.E. & Pomerening, J. R. Uncovering the role of APC-Cdh1 in generating the dynamics of S-phase onset. Mol. Biol. Cell 25, 441456 (2014).

PubMed PubMed Central Article Google Scholar

Greil, C. et al. The role of APC/CCdh1 in replication stress and origin of genomic instability. Oncogene 35, 30623070 (2016).

CAS PubMed Article Google Scholar

Garzn, J. et al. Shortage of dNTPs underlies altered replication dynamics and DNA breakage in the absence of the APC/C cofactor Cdh1. Oncogene 36, 58085818 (2017).

PubMed Article CAS Google Scholar

Kimata, Y. APC/C ubiquitin ligase: Coupling cellular differentiation to G1/G0 phase in multicellular systems. Trends Cell Biol. 29, 591603 (2019).

CAS PubMed Article Google Scholar

Sigrist, S. J. & Lehner, C. F. Drosophila fizzy-related down-regulates mitotic cyclins and is required for cell proliferation arrest and entry into endocycles. Cell 90, 671681 (1997).

CAS PubMed Article Google Scholar

Delgado-Esteban, M., Garca-Higuera, I., Maestre, C., Moreno, S. & Almeida, A. APC/C-Cdh1 coordinates neurogenesis and cortical size during development. Nat. Commun. 4, 2879 (2013).

ADS PubMed Article CAS Google Scholar

Eguren, M. et al. The APC/C cofactor Cdh1 prevents replicative stress and p53-dependent cell death in neural progenitors. Nat. Commun. 4, 2880 (2013).

ADS PubMed Article CAS Google Scholar

Holt, J. E. et al. The APC/C activator FZR1 is essential for meiotic prophase I in mice. Development 141, 13541365 (2014).

CAS PubMed Article Google Scholar

Li, W., Wu, G. & Wan, Y. The dual effects of Cdh1/APC in myogenesis. FASEB J. 21, 36063617 (2007).

CAS PubMed Article Google Scholar

Wu, G. et al. The anaphase-promoting complex coordinates initiation of lens differentiation D. Mol. Biol. Cell 18, 10181029 (2007).

CAS PubMed PubMed Central Article Google Scholar

Koulnis, M. et al. Identification and analysis of mouse erythroid progenitors using the CD71/TER119 flow-cytometric assay. J. Vis. Exp. https://doi.org/10.3791/2809 (2011).

Article PubMed PubMed Central Google Scholar

de Boer, J. et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur. J. Immunol. 33, 314325 (2003).

PubMed Article Google Scholar

Bennett, L. F., Liao, C. & Paulson, R. F. Stress Erythropoiesis Model Systems 91102 (Springer, 2018). https://doi.org/10.1007/978-1-4939-7428-3_5.

Book Google Scholar

Swartz, K. L. et al. E2F2 promotes nuclear condensation and enucleation of terminally differentiated erythroblasts. Mol. Cell. Biol. 37, 110 (2017).

Article Google Scholar

Farrs, J. et al. PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Cell Death Differ. 22, 11441157 (2015).

PubMed Article CAS Google Scholar

Liu, J. et al. Quantitative analysis of murine terminal erythroid differentiation in vivo: Novel method to study normal and disordered erythropoiesis. Blood 121, e43e49 (2013).

CAS PubMed PubMed Central Article Google Scholar

Kozar, K. et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 118, 477491 (2004).

CAS PubMed Article Google Scholar

Sankaran, V. G. et al. Cyclin D3 coordinates the cell cycle during differentiation to regulate erythrocyte size and number. Genes Dev. 26, 20752087 (2012).

CAS PubMed PubMed Central Article Google Scholar

Spike, B. T. & Macleod, K. F. The Rb tumor suppressor in stress responses and hematopoietic homeostasis. Cell Cycle 4, 4245 (2005).

CAS PubMed Article Google Scholar

Sankaran, V. G., Orkin, S. H. & Walkley, C. R. Rb intrinsically promotes erythropoiesis by coupling cell cycle exit with mitochondrial biogenesis. Genes Dev. 22, 463475 (2008).

CAS PubMed PubMed Central Article Google Scholar

Kinross, K. M., Clark, A. J., Iazzolino, R. M. & Humbert, P. O. E2f4 regulates fetal erythropoiesis through the promotion of cellular proliferation. Blood 108, 886895 (2006).

CAS PubMed Article Google Scholar

Hu, T. et al. Concomitant inactivation of Rb and E2f8 in hematopoietic stem cells synergizes to induce severe anemia. Blood 119, 45324542 (2012).

CAS PubMed PubMed Central Article Google Scholar

Ghazaryan, S. et al. Inactivation of Rb and E2f8 synergizes to trigger stressed DNA replication during erythroid terminal differentiation. Mol. Cell. Biol. 34, 28332847 (2014).

PubMed PubMed Central Article CAS Google Scholar

Alvarez, S. et al. Replication stress caused by low MCM expression limits fetal erythropoiesis and hematopoietic stem cell functionality. Nat. Commun. 6, 8548 (2015).

ADS CAS PubMed Article Google Scholar

Ishizawa, J. et al. The cell cycle regulator Cdh1 controls the pool sizes of hematopoietic stem cells and mature lineage progenitors by protecting from genotoxic stress. Cancer Sci. 102, 967974 (2011).

CAS PubMed Article Google Scholar

He, C. et al. c-myc in the hematopoietic lineage is crucial for its angiogenic function in the mouse embryo. Development 135, 24672477 (2008).

CAS PubMed Article Google Scholar

Dirlam, A., Spike, B. T. & Macleod, K. F. Deregulated E2f2 underlies cell cycle and maturation defects in retinoblastoma null erythroblasts. Mol. Cell. Biol. 27, 87138728 (2007).

CAS PubMed PubMed Central Article Google Scholar

Cohen, M. et al. Unbiased transcriptome signature of in vivo cell proliferation reveals pro- and antiproliferative gene networks. Cell Cycle 12, 29923000 (2013).

CAS PubMed PubMed Central Article Google Scholar

Boekhout, M. et al. Feedback regulation between atypical E2Fs and APC/C-Cdh1 coordinates cell cycle progression. EMBO Rep. 17, 414427 (2016).

CAS PubMed PubMed Central Article Google Scholar

Clijsters, L. et al. Cyclin F controls cell-cycle transcriptional outputs by directing the degradation of the three activator E2Fs. Mol. Cell 74, 12641277 (2019).

CAS PubMed PubMed Central Article Google Scholar

Yuan, R. et al. Cyclin F-dependent degradation of E2F7 is critical for DNA repair and G2-phase progression. EMBO J. 38, 20 (2019).

Google Scholar

Wasserman, D. et al. Cell cycle oscillators underlying orderly proteolysis of E2F8. Mol. Biol. Cell 31, 725740 (2020).

CAS PubMed PubMed Central Article Google Scholar

Choudhury, R. et al. APC/C and SCF(cyclin F) constitute a reciprocal feedback circuit controlling S-phase entry. Cell Rep. 16, 33593372 (2016).

CAS PubMed PubMed Central Article Google Scholar

Angulo-Ibez, M. et al. Erk5 contributes to maintaining the balance of cellular nucleotide levels and erythropoiesis. Cell Cycle 14, 38643876 (2015).

PubMed PubMed Central Article CAS Google Scholar

Bracken, A. P., Ciro, M., Cocito, A. & Helin, K. E2F target genes: Unraveling the biology. Trends Biochem. Sci. 29, 409417 (2004).

CAS PubMed Article Google Scholar

Hayashi, S., Lewis, P., Pevny, L. & McMahon, A. P. Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Mech. Dev. 119, S97S101 (2002).

PubMed Article Google Scholar

Follow this link:
Efficient terminal erythroid differentiation requires the APC/C cofactor Cdh1 to limit replicative stress in erythroblasts | Scientific Reports -...

Posted in Stem Cells | Comments Off on Efficient terminal erythroid differentiation requires the APC/C cofactor Cdh1 to limit replicative stress in erythroblasts | Scientific Reports -…

World Sickle Cell Day 2022: Stem Cell Transplant the only curative treatment for Sickle cell Disease – PR Newswire

Posted: June 22, 2022 at 2:18 am

BENGALURU, India, June 20, 2022 /PRNewswire/ -- DKMS BMST Foundation India is a non-profit organization dedicated to the fight against blood cancer and other blood disorders, such as thalassemia and sickle cell disease. The organization aims to give every blood disorder patient in need a second chance at life

There are as many as 2.5 million carrier of the gene (Hemoglobin AS) in India that can lead to sickle cell disease, with more than 1,25,000 actual patients spread across the country, with a much higher incidence in the tribal belt of the country. Sickle cell disease is associated with a significant risk of morbidity and premature mortality, especially among children. While in the west, a child receiving comprehensive care in high-resource settings has an estimated 99% survival into adulthood. However, in India, according to an ICMR study, about 20 per cent of children with sickle disease died by the age of two, and 30 per cent children with Sickle Cell Disease die before they reach adulthood.

Dr. Biju George, Professor & Head, Department of Haematology at CMC Vellore, "People with Sickle Cell Disease, may beat a risk of progressive organ damage, impaired quality of life, considerable morbidity in childhood, and risk of premature mortality in adulthood [median survival of 58 years]. Sickle Cell disease patients who are undergoing regular life-long blood transfusions, have the best chance of survival and cure with a blood stem cell transplant. This transplant can come from a sibling or a family member. However, there is only a 30% chance of finding a "matched" sibling donor in the same family. The remaining 70% patients look for a matching donor through a stem cell registry or donor center- a database of voluntary donors between the age group of 18 to 50 years."

Dr. Govind Eriat Nair, Consultant Hematology Hemato-Oncology and Bone Marrow Transplant Gleneagles Global BGS Hospital, Bengaluru, "If there is a fully HLA matched donor in the family, there is a 90-95% chance of cure with higher cure rates in younger children of below 12 years of age. However, due to underrepresentation of Indians in the global donor data pool, patients are unable to find a match on time. Also, the awareness about the disease is less, need of the hour is to raise the social awareness about this disease. Genetic counseling and newborn screening are the way forward. Effects of endogamy, consanguinity and role prenatal counseling needs to be addressed in primary screening."

To mark World Sickle Cell Day, Patrick Paul, CEO, DKMS BMST Foundation India said, "Sickle cell has variance and only the severe form needs a stem cell transplant. An early transplant can help patient with severe Sickle cell disease from organ damage. With rising cases in India, it is the need of the hour that stem cell transplants are made available to more patients to save lives. But due to the misconceptions and lack of awareness about blood stem cell donation, Indians are highly underrepresented in the global donor pool. This situation can only be changed by recruiting many more potential blood stem cell donors from the Indian ethnicity."

The success of a stem cell transplant depends of donor's HLA (Human Leukocyte Antigen) matching the patient. The body's immune system has proteins known as HLA to distinguish cells that belong to the body from those that do not. DKMS-BMST helps in unrelated donor transplant process which includes enrolling and counselling the donors, get their HLA typing done, facilitate search of the donors and later facilitate the blood stem cell collection and the transplant. So, far DKMS-BMST has registered over 60,000 potential donors and have helped 60 patients with second chance at life.

Register as a potential blood stem cell donor:

Healthy individuals between 18-50 years of age can register at: dkms-bmst.org/register

All it takes is five minutes of your time and a simple 3 step process:

Step 1: Visit the site, fill up an online form and you will receive a DIY swab kit at home.

Step 2: Once you receive the swab kit, fill out the consent form and take a tissue sample from the inside of your cheeks with 3 cotton swabs provided in the kit.

Step 3: Send back your swab sample in the pre-paid envelope provided.

DKMS laboratory will then analyze your tissue type and your details will be available in the global search for blood stem cell donors. If you do come up as a suitable donor, DKMS-BMST will get in touch with you straight away. Once you come up as a match, blood stem cells will be obtained from the bloodstream using a procedure called Peripheral Blood Stem Cell Collection, which is similar to a blood donation wherein only your stem cells are taken. This is a safe, non-surgical outpatient procedure.

About DKMS BMST Foundation India

A non-profit organization dedicated to the fight against blood cancer and other blood disorders, such as thalassemia and aplastic Anemia. Our aim is to improve the situation of patients suffering from blood cancer and other blood disorders in India and throughout the world, by raising awareness about blood stem cell transplantation and registering potential blood stem cell donors. By doing this DKMS-BMST provides patients in need of a blood stem cell transplant with a second chance at life.

DKMS-BMST is a joint venture of two reputed non-profit organizations: BMST (Bangalore Medical Services Trust) and DKMS, one of the largest international blood stem cell donor centres in the world. For more information, please visit dkms-bmst.org.

Media Contact:Aarohi TripathyDKMS BMST Foundation India8890103987[emailprotected]

SOURCE DKMS BMST Foundation India

Read this article:
World Sickle Cell Day 2022: Stem Cell Transplant the only curative treatment for Sickle cell Disease - PR Newswire

Posted in Stem Cells | Comments Off on World Sickle Cell Day 2022: Stem Cell Transplant the only curative treatment for Sickle cell Disease – PR Newswire

Dissecting the Complexity of the Brain at a Single Cell Level – Technology Networks

Posted: June 22, 2022 at 2:18 am

Understanding the brain requires an in-depth knowledge of its components. Advanced single-cell sequencing technologies are enabling researchers to explore the secrets of this complex and mysterious organ in unprecedented detail.

The human brain and spinal cord contain billions of different cells and connections that form intricate neural networks. Studying the brains building blocks is a fundamental step toward understanding how it functions and what can go wrong to cause disease.

The brain is very complex and we have to start at the molecular level to understand how it works, says Jiaqian Wu, associate professor at UTHealth Houston, McGovern Medical School, Texas.

By measuring multiple molecular signatures in thousands to millions of individual cells, single-cell sequencing can comprehensively characterize the diversity of brain cell types and provide insight into relationships between different cell populations. Single-cell transcriptomics enables the analysis of the abundance and sequences of RNA molecules, while epigenomics is the genome-wide mapping of DNA methylation, histone protein modification, chromatin accessibility and chromosome conformation.

We can barcode individual brain cells and examine things like gene expression or epigenetic changes to understand how each cell is regulated and how they respond to external stimuli, says Sarah Marzi, Edmond and Lily Safra research fellow at the UK DRI at Imperial College London.

Rapid developments in the experimental and computational methods of single-cell technologies are providing novel insights into differences among and within the cells that make up the brain revealing cell diversity, identifying rare subpopulations of interest and discovering unique characteristics of individual cells. Acting as a bridge between neuroscience, computational biology and systems biology, these sophisticated new tools hold the key to probing the brains inner circuitry in health and disease.

The two most common cell types in the central nervous system are neurons, which send and receive electrical and chemical signals, and glial cells, which are necessary for the healthy function of neurons. These different cell types are then further divided into additional subclasses. But despite recent progress, there is still a lack of a complete consensus or taxonomy of brain cell types.

The brain is made up of many different cell types that fill vastly different functions, says Marzi. Understanding the identity of cells requires molecular profiling to reveal tiny distinctions between cells.

In the past, people were limited to profiling whole tissue samples. While these bulk sequencing approaches can provide valuable information, they dont reveal the whole story.

Because there are so many different cell types, the molecular signals are averaged out across the population of cells, says Wu. Newer single-cell technologies are allowing a more fine-grained examination of whats going on at an individual cell level. We use computational methods to cluster cells into different cell subtypes based on their molecular signatures.

Single-cell sequencing technologies are providing researchers with powerful tools to extract genomic, transcriptomic or epigenomic information at an individual cell level. Over the past decade, technological advances have fueled exponential increases in the number of cells that can be studied, enabling the analysis of hundreds of thousands of cells in a single experiment. Many of these analyses are focused on examining gene activity within individual cells using RNA sequencing (RNA-seq) but there are still some disadvantages compared to bulk approaches.

Most single-cell technologies still have a lower sensitivity than bulk sequencing approaches, explains Wu. For example, Im interested in long non-coding RNAs, which are a very important type of regulatory RNA, but we may not capture as many of these kinds of molecules if theyre expressed at a low level.

The first and most important step in most single-cell sequencing experiments is the isolation of individual cells from a tissue sample. While such approaches can shed light on cellular relationships based on shared molecular characteristics, they dont provide any information about how cells are organized relative to each other in a tissue. But groundbreaking spatially resolved transcriptomic methods are set to revolutionize understanding of how cells are assembled in 3D within their microenvironment.

These new methods are incredibly exciting, but there is still some room for improvement, says Wu.

Even the most highly resolved methods can now achieve a resolution of perhaps around three to five cells within a tissue and so disentangling where those molecular signals are coming from at a single cell level is still challenging. Overcoming these remaining technological barriers will open a wealth of new opportunities for researchers to map gene expression in a spatial context in brain tissues as well as to take measurements of enzymatic processes and the interactions between cells, among genes, and between proteins.

Studying the blood-brain barrier is an important example, envisions Marzi. You need that spatial resolution of which cell layers onto which and whats happening in these cells as they react to pathological changes in the brain or as they develop pathology and the barrier becomes penetrable.

Researchers are using more holistic approaches to capture increasingly rich information from individual brain cells. Many of these combine RNA-seq with epigenetics methods such as assay for transposase-accessible chromatin by sequencing (ATAC-Seq), and chromatin immunoprecipitation with massively parallel sequencing (ChIP-Seq) to simultaneously capture multiomics information about gene expression along with clues about how genes are regulated at a single-cell level. But while combining single-cell technologies provides unique opportunities for probing into the complexity of the brain, it creates computational challenges around integrating and interpreting the enormous multiple datasets generated.

Wus laboratory combines neuroscience, stem cell biology and systems biology involving genomics, bioinformatics and functional assays to unravel gene transcription and regulatory mechanisms in the brain and spinal cord.

Were studying gene expression and regulation using single-cell sequencing methods and integrating different datasets to gain a more comprehensive understanding, explains Wu. My laboratory is self-sufficient were split into two halves; one half is wet lab and the other is dry lab. Weve set up our own bioinformatics pipeline to analyze the different types of data and make sense of it.

Marzis lab uses a combination of wet and computational genomics approaches to understand the regulatory consequences of environmental and genetic risk factors for Alzheimers and Parkinsons disease, both neurodegenerative disorders.

This is a field where you need to use a lot of data science and quantitative approaches to learn new things because the datasets were creating are so large and complicated that you need to apply solid statistical methods to analyze it, she explains.

Given the remarkable progress in machine learning technology, such techniques are also currently being introduced for single-cell analysis to overcome challenges and make more effective use of its results with encouraging results so far.

Since the first single-cell RNA-seq study was published in 2009, there has been an explosion in conducting such studies across biomedical research and the field of neuroscience is no exception. Novel single-cell sequencing technologies are beginning to uncover the comprehensive landscape of brain cell type diversity and are predicted to drive huge progress in understanding this complex organ in coming years.

Scientists are applying these methods to create detailed atlases of every cell type in the brain across time from development to adulthood. For example, one recent study performed RNA-seq across regions of the developing human brain to provide a comprehensive molecular and spatial analysis of the early stages of brain and cortical development. Another applied whole-brain spatial transcriptomics to deduce a molecular atlas of the adult mouse brain. Such resources will be hugely valuable for researchers studying normal brain development and disease pathology.

Single-cell approaches are really powerful, says Marzi. Theyre providing us with the tools to identify the key players behind unhealthy cell responses, and finding ways to change them.

See original here:
Dissecting the Complexity of the Brain at a Single Cell Level - Technology Networks

Posted in Stem Cells | Comments Off on Dissecting the Complexity of the Brain at a Single Cell Level – Technology Networks

Amniotics presents positive preclinical data on stem cell treatment for chemotherapy-induced peripheral neuropathy at ICRBE 2022 – Marketscreener.com

Posted: June 22, 2022 at 2:18 am

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that an abstract with new promising preclinical data on the treatment of chemotherapy-induced peripheral neuropathy (CIPN) with mesenchymal stem cells (MSC) has been accepted for a poster presentation at the 16th International Conference on Regenerative Biology and Engineering (ICRBE) taking place on July 28-29 in Zurich, Switzerland.

The abstract, titled Amniotic Fluid Mesenchymal Stem Cells Selected for Neural Specificity Ameliorates Chemotherapy Induced Hearing Loss and Pain Perception, will be presented by Amniotics COO Jan Talts at ICRBE. Other authors include Kre Engkilde, CEO of Amniotics. The presentation includes preclinical results showing that treatment with MSC selected for neural specificity (CogniStemTM) have significant positive efficacy on chemotherapy-induced hearing loss and chemotherapy-induced neuropathic pain.The results show the potential wide usages of tissue specific/relevant mesenchymal stem cells from amniotic fluid as treatment in connection with cancer therapy and represent further validation of Amniotics platform and our therapeutic approach. Were excited about the data presented and will now evaluate how to leverage on these findings, says Jan Talts, COO at Amniotics.Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by anti-neoplastic agents, with a prevalence between 19 and 85 percent. Clinically, CIPN is a mostly sensory neuropathy leading to pain and to motor and autonomic changes. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors, especially because currently there is no single effective method of preventing CIPN. Hearing loss is the most common form of sensory impairment in humans and can be caused by ototoxic chemical compounds such as chemotherapy (platinum-based antineoplastic agents).

Go here to read the rest:
Amniotics presents positive preclinical data on stem cell treatment for chemotherapy-induced peripheral neuropathy at ICRBE 2022 - Marketscreener.com

Posted in Stem Cells | Comments Off on Amniotics presents positive preclinical data on stem cell treatment for chemotherapy-induced peripheral neuropathy at ICRBE 2022 – Marketscreener.com

CBD And CBG Show Promising Results In Treating Glioblastoma Brain Tumors – The Fresh Toast

Posted: June 22, 2022 at 2:17 am

By Nina Zdinjak

MGC Pharmaceuticals , a publicly-traded cannabis company, recently finalized pre-clinical trial research ofcannabinoids as a potential treatment for glioblastoma,anaggressive brain cancer.Theresults were positive,reported CityA.M.

The European-based bio-pharma company specializing in the production and development of phytomedicines said that the three-year in-vitro trial delivered outstanding results.

The research, conducted in collaboration with theNational Institute of Biology in Slovenia with30 biopsy samples from 18 patients,firstexamined how cannabinoids such as CBD can be used as a treatment for cancerous tumors. MGC also researched THC and later replaced it with cannabigerol, known as CBG, which has no known psychotropic effects.

The study took more than 5,800 cell tests to determine the most efficient concentration and ratios of CBD and CBGin the treatment formulation.

The results revealed the efficacy of cannabinoidsin treating glioblastoma, as well as the most efficient ratio of CBD:CBG in inhibiting the tumors viability, causing a cascade of biological processes resulting in the death of glioblastoma and stem cells,reported BusinessCann. This is important because glioblastoma stem cells are the primary cause of the diseases progressionand areresistant to standard treatments.Glioblastoma is the most common, fast-growing, and aggressive brain tumor. Composed of diverse cell types, the prognosis is always poor.

RELATED: CBD Restricts Tumor Growth In Cancer Patients, Finds New Study

The results of this trial are enormously exciting both for the company, and for the treatment of fatal cancerous tumors, saidRoby Zomer,co-founder and managing director at MGC Pharmaceuticals.

MGC Pharmas research has demonstrated the effect of naturally derived cannabinoid products on stage IV brain tumors without the use of toxic chemotherapy components. We are proud of the work achieved thus far and are looking forward to advancing our proprietary formulation to the next stage of clinical trials.

This is not the first successful research on the potential of CBD as a treatment for this type of brain tumor.

Researchers at theMedical College of Georgia at Augusta University, released astudyin December revealing thatinhaled CBD shrunkthe size of glioblastoma tumorsin an animal model.

The study suggested thatinhaled CBD reduces the size of glioblastomathrough the reduction of the essential support of its microenvironment. Researcherschose the inhaled approach to make sure the compound found in the cannabis plant reached the brain.

RELATED: CBG Mania: What Are the Best Ways To Use And Consume CBG?

We saw a significant reduction in the size of the tumor and its microenvironment was different, after only seven days of treatment,saidDr.Babak Baban,immunologist and associate dean for research at the Dental College of Georgia at Augusta University.

In eight days the aggressive brain tumor was formed in the brain of the mice, and the following day they started treating them with CBD via inhalation or placebo. The researchers discovered thatCBD altered the tumors ecosystem, or supportive tumor microenvironment, and restored levels of inflammation that attack glioblastoma.

RELATED: Cannabis-Based Sativex Mouth Spray To Treat Brain Tumors?

It is about immune balance, said Baban, the corresponding author of the study.

He explained that the human immune system is regularly fighting cancerous or precancerous cells, but when a tumor is completely established, it takes charge. This means that the tumor creates a state of more chronic inflammation that ends up protecting it from the immune system.

While further research is needed, these results are a great start as they offerhope to theapproximately250,000people worldwide struggling with this devastating condition.

This article originally appeared on Benzinga and has been reposted with permission.

Go here to see the original:
CBD And CBG Show Promising Results In Treating Glioblastoma Brain Tumors - The Fresh Toast

Posted in Georgia Stem Cells | Comments Off on CBD And CBG Show Promising Results In Treating Glioblastoma Brain Tumors – The Fresh Toast

Complementary and Integrative Medicine for Migraine – Medscape

Posted: June 22, 2022 at 2:15 am

This transcript has been edited for clarity.

Anna Pace, MD: Hi, everyone, and welcome. My name is Dr Anna Pace. I'm an assistant professor of neurology at the Icahn School of Medicine at Mount Sinai, and I direct the Headache Medicine Fellowship at Mount Sinai Hospital. Today, I'm lucky enough to be joined by my illustrious colleague, Dr Zhang.

Dr Zhang, would you like to introduce yourself?

Niushen Zhang, MD: Hi, Dr Pace. It's great to be here. I'm Dr Niushen Zhang. I'm a clinical assistant professor of neurology. I'm also the chief of headache medicine at Stanford University. Great to be here.

Pace: Today, we're going to be talking about complementary and integrative medicine for migraine. I think this is a topic that has sparked a lot of interest, especially on the patient side over the last couple of years. Dr Zhang, can you tell me a little bit about what exactly complementary and integrative medicine is?

Zhang: There are actually many definitions of it. What we generally think about are nonpharmaceutical treatment approaches or healthcare practices that may not be part of conventional medicine. The American Board of Integrative Medicine gives a very well-rounded definition of this, in which they say that it's a practice of medicine that focuses on the whole person, and it should be informed by evidence and make use of all of the appropriate treatment approaches that can help our patients achieve optimal health.

The name that we use to describe this field of medicine has changed over time. Initially, it was alternative medicine, then it was called complementary and alternative medicine, or CAM. The most recent term that we use is complementary and integrative medicine.

Pace: Or CIM, for short. I think CIM, based on what you're describing, sounds like it would fit well with headache medicine, in general, when we're thinking about all of the different factors that can potentially contribute to or affect a person's headache frequency. Some of the things that we always think about are lifestyle factors that can affect headaches.

Do you have any data or anything you'd like to talk about in terms of some of the different lifestyle factors that patients can work on when they are looking to try to reduce their headache frequency?

Zhang: First, we always want to think about which patients are a best fit for this type of treatment. We think about patients who may not have had adequate responses to their pharmaceutical treatments, who have poor tolerance to these treatments, or maybe some medical contraindication to medications. We also think about people who may be pregnant or lactating or planning pregnancy. These treatments can also be helpful for people who have medication overuse headache or exhibit significant stress and may not have adequate stress coping skills.

Really, the foundation is the lifestyle modifications. The way that I explain it to patients is basically your migraine brain is hypersensitive, especially to change. What it likes is a very regular and predictable schedule for eating, sleeping, and exercise.

Specifically, what we see for exercise is that about 20 minutes a day of aerobic exercise can actually decrease headache frequency and severity. This could be anything from devoted time to walking, hiking, biking, or swimming. Those can all be very helpful.

For sleep, poor sleep quality, including things like insomnia, can affect about 30% of patients with migraine. In our clinic, we always screen for any potential underlying sleep disorders, like sleep apnea. We want to make sure our patients receive appropriate evaluations and treatment for those conditions. What we find most helpful with sleep is just keeping the same bedtime and wake-up time every day, Monday through Sunday.

Of course, we get many questions about food and nutrition. The truth is the evidence is just not strong in this area at this time, for any specific dietary interventions. We always counsel our patients to keep a very regular and consistent meal schedule throughout the day and to avoid skipping meals. Patients also love to ask about food triggers, but the evidence is not strong for what foods must be avoided.

In practice, we find that food triggers are very individual for people. If someone finds that a certain food consistently triggers their migraines, then it would make sense to avoid that food, but in general, we don't encourage people to restrict their diet.

Pace: Exercise and sleep come up often in my clinic as well. Particularly for patients who find that exercise may trigger their attacks or they're hesitant to do any exercise because their attacks are so frequent, I often recommend gentler, low-impact exercises, like yoga, tai chi, or swimming, for example, which I think people find a little bit easier to warm up to or incorporate into their routine.

And really focusing on good sleep hygiene, and even things like trying to wind down before bed and having some type of routine, is really helpful. I have had a number of patients come to me and ask, "Is there anything, like vitamins or herbal supplements, that I can take to try to help prevent my attacks?" There is quite a number of them that have good evidence. What do you usually recommend for your patients?

Zhang: I'm glad you brought that up. There are, I would say, four that are evidence-based and very helpful for our patients. One of them is magnesium. That one has a level B recommendation from the American Academy of Neurology (AAN)/American Headache Society (AHS). We think it helps with calming down neuronal hyperexcitability and preventing cortical spreading depression. Some of the formulations we like are magnesium glycinate, magnesium oxide, and citrate. We do want to watch for any loose stool or diarrhea, because those are some of the common side effects that can potentially happen. The daily dosing is about 200-600 mg/d.

Other than magnesium, we also have vitamin B2 or riboflavin. That also has a level B recommendation, and it's well-tolerated. Some people do get very bright orange or yellow urine when they take it, and the dosing is around 400 mg. There's also coenzyme Q10, which has level C recommendation from AAN/AHS. It plays a role in the electron transport chain and may play an important role in sustaining mitochondrial energy stores. It's also very well-tolerated, and the daily dosing is about 300 mg.

The last one we have is something called feverfew, which is a type of chrysanthemum. This also has a level B recommendation. We think this may have some anti-inflammatory properties. Some people do get gastrointestinal (GI) side effects with that, so you do have to watch out. We don't recommend this one during pregnancy because it can cause early contractions and potentially miscarriage. The daily dosing for that is 50-300 mg.

Pace: It's great that there are so many different nutraceutical options for migraine prevention. I personally find the combination of magnesium and riboflavin to be a good one that I tend to start with. I think nutraceuticals come up quite often. I have many patients who ask me about them. Are there any patients, in particular, whom you think would benefit most from nutraceuticals?

Zhang: Similar to what we talked about before, many of our patients just don't tolerate some of the pharmaceutical treatments that we have, so this would be a good option to start with. One thing I always ask my patients to keep in mind is that the improvement can be gradual with these supplements. Really, like any preventive treatment, you want to give it up to 3 months before someone may see maximum benefit.

Pace: Agreed. I think it's hard sometimes to wait that long, but when they do, it really can help. Another type of CIM treatment that has really great evidence in migraine prevention includes the behavioral therapies, which brings to mind things like cognitive-behavioral therapy. I'm curious what your thoughts are about those and whether or not you recommend patients to utilize them?

Zhang: I think those are terrific options. Honestly, I think one of the challenges for providers is how to broach this topic without making your patients feel like you're dismissing their experience as psychiatric or psychological. I think one way to approach this is to help your patients understand that the contributors to their headaches are usually partial and additive, and that things like stress, anxiety, and mood disorders can have a significant impact on their headaches.

That's why it's really important that we find effective ways to address those. What's great is that now we have the highest level of evidence showing that specific biobehavioral treatments, such as cognitive-behavioral therapy, biofeedback, and relaxation training, are all effective preventive treatments for migraine.

Pace: As far as I understand, it sounds like patients who have migraine and who may also have anxiety and depression may benefit from these. Do you ever see patients who don't have a history of anxiety or depression utilize any of these therapies and find them helpful just for migraine?

Zhang: Absolutely. I would say relaxation training and also biofeedback. These are great because you can not only use them as a preventive treatment things that you practice on a daily basis for prevention but also reach for them as acute treatment tools when you feel that migraine escalating or the onset of migraine.

Pace: I think that sounds great, and I agree. I find that sometimes broaching this topic with patients can be a bit challenging because on the one hand, you want to be able to validate their experience, but at the same time help to target some of the potential mood components of their presentation or the anxiety that comes with having a migraine attack with aura, which I see very commonly and I'm sure you probably do as well. Using things like relaxation therapy in the moment during an aura, I think, can be incredibly useful.

One of the other things that I always get asked about is acupuncture and whether or not there is evidence for that in terms of its efficacy in helping with migraine prevention. I seem to get that question from many of my pregnant patients. Do you have any experience recommending acupuncture to patients? What do you think about the data for that?

Zhang: We are very data-driven and we want to provide evidence-based treatments for our patients. Acupuncture has pretty good evidence for its use as a preventive treatment in episodic migraine. There's still sparse evidence for using it to treat chronic migraine or to use it as an acute treatment.

When it comes to treating episodic migraine with acupuncture, there's an excellent 2016 Cochrane review that nicely summarizes the evidence for acupuncture for this treatment. They looked at 22 trials with almost 5000 patients and found that acupuncture is slightly more effective than sham in reducing frequency of headaches and at least similarly effective as some of our standard prophylactic medications.

Pace: That's great. As far as I know about the data, it seems like it would be a good option in addition to, perhaps, the traditional therapies that we are using, like oral medications. Similarly, yoga also comes up in the same conversation whether yoga can be useful. Again, many of my pregnant patients ask this question. Do you ever recommend yoga to patients?

Zhang: With yoga, I think there's still much we have to learn about in terms of how it helps our patients with migraine. At this time, we just don't have that much robust evidence for that.

There was a randomized clinical trial published in Neurology in 2020 that looked at the effect of yoga as an add-on therapy for episodic migraine. They had two groups. One was a medical therapy group, and the other underwent medical therapy for migraine treatment, as well as yoga. They had the yoga group practice a predesigned yoga intervention 3 days per week for 1 month with an instructor at a center. This was followed by, I think, 5 days per week for 2 months at home. They looked at over 100 patients for this study.

In the end, when they compared the medical therapy group with the yoga group, the yoga group showed a significant decrease in headache frequency, intensity, and some of the migraine disability scores. The conclusion was that yoga, as an add-on therapy for episodic migraine, may be superior to medical therapy alone. I think this is a very promising beginning in terms of the research, and I really hope that we get more studies like this done in the future.

Pace: Yes. I think it illustrates an important concept that I think many of us ascribe to, in that it's really important to think about the patient, what their lifestyle is like, and what they feel comfortable with in terms of a treatment regimen and how important it is to really create an individualized plan for them.

I personally use, often, a combination of pharmacologic treatment and nonpharmacologic treatments, so the fact that that study showed that yoga was great in addition to traditional migraine therapy hammers that point home for me, in terms of using even some of the other therapies that we've talked about in addition to our traditional oral or injectable therapies for migraine. Would you agree?

Zhang: I totally agree, Dr Pace. I think some of the most helpful treatment plans that we develop for our patients are those that integrate both pharmacologic tools and the nonpharmacologic tools that we have. Part of why I love headache medicine is that we actually get to personalize these treatments for our patients.

Pace: I completely agree. I think that's a good place for us to end. We thank you all very much for joining us.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

More:
Complementary and Integrative Medicine for Migraine - Medscape

Posted in Integrative Medicine | Comments Off on Complementary and Integrative Medicine for Migraine – Medscape

Yoga is now being absorbed into integrative medicine rather than just as an exercise: Karan Talreja – ETHealthWorld

Posted: June 22, 2022 at 2:15 am

Shahid Akhter, editor, ETHealthworld, spoke to Karan Talreja, Founder and Managing Director of Reset Tech, to find out about yoga's global prominence and how it is becoming part of health care protocol by way of integrative medicine.

Post Pandemic: Ayurveda & Yoga The antiquity of Ayurveda and Yoga has been known for the longest time. However, come Covid, there has been a sudden understanding of the requirement for strong immunity, and Yoga and Ayurveda have taken a major dominance in this field. People understand that by following Yoga practices regularly and eating the right kind of food, their immunity can be maintained to a very high level. And, that has really helped them have milder symptoms during Covid as compared to people who didnt follow a healthy lifestyle.

Also, talking about the treatment of Covid, many Covid centers provided Yoga, breathing and Pranayamas to patients, and that really helped them heal much better and faster. During Covid, several states adopted Yoga as a treatment method for patients infected with the virus. In fact, the state of Karnataka included Yoga as a part of the integrative treatment process; and it was made compulsory at most Covid centers for patients to include Yoga and Pranayama on a regular basis.

The Ayush ministry has tried its best to make Yoga available to every citizen within the country. The government is also launching a wonderful initiative which is the Ayush visa. For the very first time, people will be able to come into the country to obtain traditional forms of treatment through the Ayush visa. Also, through the ICCR, the government is sending teachers of Indian culture across the globe. This is very good because what has been observed is that Yoga has become very famous across the world; but at the same time, its true essence has been diluted.

Currently through (TIC)Teachers of Indian culture, the true essence of Yoga will be transported globally and these teachers would be responsible for teaching Yoga and hosting several Yoga-based events across the world, explaining how Yoga truly works. Another good thing that has happened in the last 7 years after Yoga has become popular globally is that a lot of research is now being done on the benefits of Yoga as a form of healing. In fact, the WHO has taken Yoga very seriously and is accepting it as a form of healing. The very first center of traditional treatment was launched in Jamnagar and the WHO chief was there for the same.

Yoga: Global Trends Yoga is becoming more and more popular in the Western world, more than it is in India. On a recent visit to New York, I was really surprised to see that one of the leading fitness centers there runs 7 classes of Yoga a day, and each one of them is fully packed.

I havent seen that kind of excitement in Yoga centers in India. To add to this, the medical research institutes and facilities in America are taking a deep dive into the benefits of Yoga for healing.

Anderson Cancer Center, which is the number one cancer hospital in the world has started offering Yoga as a part of the integrated treatment for cancer patients. And, once they move into remission it becomes a major form of healing for them. Besides this, a lot of universities in the US are doing research on Yoga in collaboration with Indian universities. What is also very surprising to me is that the first Yoga app has come from the US and not from India.

Yoga Online: Advancements Yoga online is a wonderful concept because the problem we face is that we have few excellent teachers of Yoga, and a huge population that wants to benefit from it.

So, what do we do? We just go to the teacher next door, and try to start learning from them. What Yoga online is going to do is bring access to the best teachers to the world audience. So, wherever you are in the world, you will now have access to the best teachers who have been practicing Yoga in its purest form for several years.

There is of course a disadvantage. People generally have this question - How will my Yoga posture be correct if Im learning digitally - compared to a physical space where my teacher is looking at me and correcting my posture if Im wrong? We have a solution to that. Technology is a game changer. Our technology will also identify posture.

There will be several dimensions of the human body which will get captured by the phone camera. The postures will be taken into the system. And wherever people are going wrong, the posture will be corrected.

Going forward, it will make life very easy for people not to miss a class, because you can definitely have the class in your house. So, you dont have to worry about traffic, travel time, and all of that. Besides that, if you miss a class, you can always catch up on the pre-recorded sessions that we have; or just join the class whenever you want to. This can be very difficult and awkward in a physical setup. So, you will benefit much more with online Yoga than you have done otherwise.

Reset Tech: Vision and Growth In 2017 we started a center in Mumbai called Reset which helped people heal naturally with traditional forms of treatment. We did very, very well. In 2020 when the pandemic hit us, we realized that we faced challenges because of the lack of physical presence of members. We decided to now move digital and cater to the world audience with our offering.

We have been working on a completely digital platform called Aayu which will help take Ayurveda, Yoga, and other forms of traditional treatment to the world. We have been creating several programs to heal certain lifestyle diseases. So, what will also benefit is it will not just be a mere experience it will be a lifestyle; because you can do your practices within your house.

Whether there is a lockdown, no lockdown, whether you have time to visit a center or not; everything can be done in your house, at one place. So that is what we have been doing at Reset Tech, and we look forward to healing the world, or at least offering the ability to heal at your doorstep.

Reset Tech: Digital Expansion At Aayu we want to completely change the way people look at digital healing. We are focusing a lot on technology to make healing much more accessible to everybody in the world.

Also, assessments and progress reports that people look forward to will be generated because it's a completely digital program and you can assess yourself through technology. Our artificial intelligence will also offer you services that you need, not just what you want.

Very often, we're looking at healing in a particular disease but we realize that there is some meditation, some Pranayama, or maybe certain sleep stories which can help you heal better and faster. So, we're working at targeting the entire human body as one unit, and not just the problem that the person is facing. This is something that is easily possible through technology.

We are also working on a mood tracking system where just by capturing an image, you will understand what mood you are going through and our AI will provide you solutions to improve your mood. And besides this, we are also looking at having a global launch, where we will be available in multiple languages. Very often the best knowledge is available, but in limited languages. So, people who don't understand or cannot relate to that language are not able to take advantage of those practices.

To give an example, Yoga content is either in Hindi or in English globally, but we would like to go in regional languages in India, and also the most popular languages globally. So, these are some of the things that we're doing that would disrupt the way wellness has been offered to people, and this is possible through technology. And again, we look forward to healing the world through our App.

See original here:
Yoga is now being absorbed into integrative medicine rather than just as an exercise: Karan Talreja - ETHealthWorld

Posted in Integrative Medicine | Comments Off on Yoga is now being absorbed into integrative medicine rather than just as an exercise: Karan Talreja – ETHealthWorld

Successes and Challenges With Using PDTs – AJMC.com Managed Markets Network

Posted: June 22, 2022 at 2:15 am

Arwen Podesta, MD: I'm a psychiatrist. I specialize in a whole slew of things: holistic integrative medicine, addiction medicine, forensic psychiatry, adult general psychiatry. I love using all tools in the toolbox. I want my patients to use something that is available to them 24/7. I want my patients to have therapy available, and it just hasn't been, especially with closures and people stepping back and not having live visits through the pandemic. I have adopted using prescription digital therapeutics for both my practice in the field of addiction and sleep. Everyone has sleep issues. Everyone wants a medicine for sleep. I use things that have very few-to-no adverse events, and most medications have an adverse event that could be possible.

I have used reSET, which is addiction cognitive behavioral therapy and contingency management app. I've used that in my practice for a while, as well as reSET-O, which is the same but is FDA approved for those with opioid use disorderspecifically those on a medication-assisted treatment for opioid use disorder; an example is buprenorphine. There is 12-week cognitive behavioral therapy on your app. It's about an hour a week per patient. I look at my clinician dashboard and keep up with what the patient's doing, see how they're progressing, see their pressure points and relapse potentials, and then orient my treatment accordingly. This is great because 90% of relapses don't occur when they're leaving my office. They [can] feel great then, but I'm [not] seeing them every day and not even every week, necessarily. Most relapses occur when stress happens, when people are not able to sleep, so their brain is going back to the easiest path of least resistance: going and getting that drug. Most relapses happen outside clinic hours, so they are able to use this tool on their device 24/7.

With addiction, we need treatment on demand. If someone has to wait to get into therapy, then their addiction is probably going to make rationalized excuses as to why they shouldn't go and should continue to use. Often, we mistreat on demand and when we don't have something like a 24/7 digital therapeutic. I don't know many sponsors that are going to be available at 2 A.M. every morning. [Because I use reSET and reSET-O,] I was oriented to PSM [propriospinal myoclonus at sleep onset] risk, which is a cognitive behavioral therapy for insomnia. It is wildly successful and has a different type of cognitive-behavioral therapy that is very specific and oriented for insomnia. It's been used by the VA [US Veterans Affairs Department] for [years, as well as] sleep specialists that are trained in it, but it is [programmed] for those that use this FDA-authorized prescription digital therapeutic.

What are some challenges that I've had with getting patients to buy in? First, patients are on their phone frequently, but a lot of my patients in psychiatry and addiction feel that when I'm speaking about phone use, theyre judged. They feel like [using the] phone is bad and that I'm going to want them to be off of their device. That's not true. I use motivational interviewing to discuss everything new with patients, and that's what I do for discussing prescription digital therapeutics. How long are they going to have to use it? How many hours a day? What's required? What's interesting about reSET & reSET-O? Is it also contingency management? When patients get onboarded, which is a super easy process, they get a gift card depending on the prescriber. That makes it more salient, so the patient wants to use it more. They also get a prize at random times when they finish certain modules, so there's that for those two therapeutics.

Most of my patients want a quick fix for sleep. It might take 12 weeks before theyve improved their sleep, but it usually takes much less than that. I use different types of non-scheduled medication to help them get sleep [immediately, as well as] supplements and other tools, and then use the app in tandem. Ive had several CEOs, attorneys, etc, come to me for sleep issues that know they're smart and have read about sleep hygiene, but then a particular module just got them. I get to see it on the clinician dashboard. I see that in module 2, she went from poor sleep efficacy to much higher. I ask her how that feels, how it's sustainable, and bring that to the therapeutic alignment.

There have been some barriers in adopting and adapting with PDTs [prescription digital therapeutics]. Theres a concern as far as how we're going to get this paid for. There's some attention deficitprescription digital therapeutics for kids that I know some parents are apt to pay out of pocket for because they work well. [Paying out of pocket is] not [common for] every patient. Most of this is based on some sort of cognitive-behavioral therapy, and payers tend to pay for therapy but not algorithmize therapy through a prescription digital therapeutic at this time. [Both payers and prescribers are barriers.] This can't be prescribed by a therapist or nutritionist. It can't be prescribed by a nurse. It must be prescribed by someone who has their license to prescribe medications. What do prescribers know about PDTs? When I've brought this to message boards and ask, What does everyone feel about a prescription digital therapeutic? something like 6080% of the physicians and psychiatrists responded {~100 people], said they don't know enough about them.

Trainings are essential. This started in 2016; it's new, and if we don't learn it in medical school, we're not going to use it in our practice unless we get access to it or hear success stories. If we don't have a mentor during medical school or residency that is teaching us, we're not going to use it. To have adoption of PDTs, we need great messaging with the prescribers but to also let the patients lead the way. We're at the beginning of the wave, and we've got some more education to do.

This transcript has been edited for clarity.

See the rest here:
Successes and Challenges With Using PDTs - AJMC.com Managed Markets Network

Posted in Integrative Medicine | Comments Off on Successes and Challenges With Using PDTs – AJMC.com Managed Markets Network

Never Take This After Age 50, Warn Experts Eat This Not That – Eat This, Not That

Posted: June 22, 2022 at 2:15 am

Age matters when it comes to taking certain medications and supplements. According to the U.S. Drug and Food Administration "As you get older, body changes can affect the way medicines are absorbed and used. For example, changes in the digestive system can affect how fast medicines enter the bloodstream. Changes in body weight can influence the amount of medicine you need to take and how long it stays in your body. The circulatory system may slow down, which can affect how fast drugs get to the liver and kidneys. The liver and kidneys also may work more slowly, affecting the way a drug breaks down and is removed from the body." Knowing which medications and supplements to stay away from as we get older could make a big difference healthwise and experts reveal to us which ones to avoid and why. Read onand to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID.

Dr. Jeff Gladd, M.D., chief medical officer at Fullscript, and integrative medicine physician tells Eat This, Not That! Health, "Iron is a mineral found in many multivitamins formulated for women of reproductive age; however, iron supplementation is generally not necessary for postmenopausal women and women over 50. Once a woman enters her 50s and no longer menstruates, her iron requirements decline by nearly 45%. While iron plays an essential role in the formation of red blood cells, consuming excess iron can affect zinc absorption and contribute to unpleasant gastrointestinal symptoms such as constipation, diarrhea, nausea, vomiting, and abdominal pain.

All of that being said, I find it necessary to test all patients' levels of total body iron to assess optimal status. While the likelihood of deficiency is lower in men as well as women over 50 years old, the intake from the diet and health of the digestive tract for absorption may still be playing a role in deficiency."

Dr. Gladd explains, "High blood pressure (hypertension) affects nearly half of adults, and the risk of developing high blood pressure increases with age. Adults with high blood pressure should avoid taking licorice root, a popular herbal supplement often used to support adrenal gland function.

Research shows that licorice root can elevate blood pressure and interact with blood pressure medications. Licorice root can also reduce potassium levels, an important mineral that helps regulate blood pressure.

Licorice is also used for digestive health, as it provides support for mild irritation of the digestive lining. This should always be in the deglycyrrhizinated licorice (DGL) form. Removing glycyrrhizin ensures that the blood pressure-impacting part of the root is removed and is often safe to be taken by most. It is best to work with an integrative medicine provider who can make personal recommendations and help guide the risks and benefits of therapies as well as monitor their impact on one's health."

Dr. David Culpepper, MD and Clinical DIrector of LifeMD shares, "After 50, I would exercise caution when taking B-complex vitamins. Vitamin B3 (niacin) and Vitamin B9 (folate) in particular can build up and put a strain on your liver when it tries to flush the excess out of your bloodstream. As many people are concerned primarily about getting enough B12 because of its benefits to the brain and blood cells, I would suggest taking a B12 alone and skipping the B-complex."

Dr. Culpepper says, "As far as medications, I would caution those over 50 against using the decongestant pseudoephedrine. This over the counter medication is a vasoconstrictor, meaning it narrows the blood vessels. This can cause an increase in blood pressure, which can be dangerous for those over 50, especially anyone at risk for heart disease."

Dr. Culpepper explains, "I would offer similar cautions against many herbal stimulants for those over 50. Many of these also cause vasoconstriction and the associated hypertension (high blood pressure). There are many herbal supplements in this category, but some of the common ones are ginkgo biloba, ginseng, Siberian ginseng, guarana, and gotu kola. Many of these are found in energy drinks and other products marketed for an energy boost. Always read the ingredients on such products, and keep in mind that a product touted for its energy boosting properties is likely to cause a boost in your blood pressure as well."

Karin Ashley, an Integrative Women's Health Nurse Practitioner explains, "Folic acid is a synthetic version of folate, also known as vitamin B9. Folic acid, along with other vitamins, is added to a number of foods to fortify them. Supplementing folic acid in addition to the fortified foods can cause an imbalance in metabolism, leading to vitamin B12 deficiency. Older adults are more prone to vitamin B12 deficiency to begin with due to the natural decrease in stomach acid, which is needed to absorb nutrients from food. Risk of over-supplementation can be decreased by eating less foods (mainly breads and cereals) that have 'enriched flour' in the ingredient list."6254a4d1642c605c54bf1cab17d50f1e

Ashley emphasizes, "It's really important for consumers, especially older adults, to read labels on nutritional supplements. It is true that older adults may need to supplement protein, fats, vitamins, and minerals, but they should be selective about the source. Many supplement shakes have added artificial sweeteners like acesulfame K and aspartame, which have been associated with an increased risk of stroke and dementia, two things that older adults are at higher risk for. These sweeteners are also added to beverages and foods labeled 'diet' and 'low sugar,' so check those labels!" And to protect your life and the lives of others, don't visit any of these 35 Places You're Most Likely to Catch COVID.

Heather Newgen

View post:
Never Take This After Age 50, Warn Experts Eat This Not That - Eat This, Not That

Posted in Integrative Medicine | Comments Off on Never Take This After Age 50, Warn Experts Eat This Not That – Eat This, Not That

Sheffield student wins national award for innovative palliative care research – University of Sheffield News

Posted: June 22, 2022 at 2:15 am

A medical student from the University of Sheffield has won a national award for her research into understanding the experiences and needs of palliative care patients.

A medical student from the University of Sheffield has won a national award for her research into understanding the experiences and needs of palliative care patients and the impact on their healthcare.

Isabel Leach, a fourth-year medical student at the University of Sheffield, was awarded the George Lewith Prize by the National Institute for Health and Care Research School for Primary Care Research (NIHR SPCR). The annual, national prize was created in memory of internationally-renowned practitioner, researcher and lecturer in complementary and integrative medicine, Professor George Lewith.

During her research, Isabel interviewed patients and their carers and identified there are often barriers in understanding the term 'palliative care' and prognosis uncertainty. She found that identifying palliative care needs is a highly individual experience where compassionate and open communication is key. The research also showed that implications of identification for future healthcare vary and that proactive primary care is integral to meaningful identification.

Isabel Leach, from the University of Sheffields Department of Oncology and Metabolism, said: The purpose of my research was to understand the experiences of patients in the identification of their palliative care needs and the impact this has had on their future healthcare.

Primary healthcare teams deliver the majority of palliative and end-of-life care in the community and there is growing interest in the use of palliative care identification tools in primary care to identify patients with unmet palliative care needs.

However, there is no previous research into the experiences and perspectives of patients about being identified as needing palliative care; this study addresses that gap.

Although palliative care is a sensitive and sometimes upsetting topic to talk about, I really enjoyed conducting interviews and recognised the great privilege it is to listen to and learn from people's stories.

Recommendations from Isabels research include:

Dr Sarah Mitchell, one of Isabels supervisors from the University of Sheffields Department of Oncology and Metabolism, said: It is fantastic to see Isabel's work recognised with this national NIHR award, and a first for Sheffield. It has been a privilege to supervise Isabel. She has shown clear commitment, motivation and a desire to improve palliative care through patient-centered research.

Isabel's research has provided new insights and valuable understanding into the experience of patients and carers of the identification of palliative care needs and the impact on their future healthcare, beneficial or not.

The work will inform improvements of identification, delivery and training in palliative care in primary care. Isabel has plans to develop patient information, information resources for students already had the opportunity to highlight the importance and relevance of her work in national research and policy (NHS England) meetings.

Isabel is set to present her research at the Society for Academic Primary Care Annual Scientific Meeting 4-6 July 2022 and is sharing her findings at the University of Sheffield Medical School Annual Research Meeting on 13-14 June 2022.

In August, she will return to studying medicine for her final two years of training but she hopes to continue to be involved in patient-centred research in primary care and would like to pursue a career as an academic GP when she graduates.

I am passionate about patient-centred research and hope that this project will lead to improvements in patient care.

Isabel Leach

University of Sheffield, Medical Student

Isabel added: I am delighted to have been awarded the George Lewith Prize for my research investigating the views and experiences of patients in the identification of their palliative care needs.

It is an honour to be recognised for my work by the NIHR School for Primary Care Research; knowing that my research has been recognised nationally is really exciting.

I'd like to thank all my supervisors, in particular Dr Sarah Mitchell who has been really supportive throughout.

Continue reading here:
Sheffield student wins national award for innovative palliative care research - University of Sheffield News

Posted in Integrative Medicine | Comments Off on Sheffield student wins national award for innovative palliative care research – University of Sheffield News